nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—ABCB1—colon cancer	0.335	1	CbGaD
Fluvoxamine—CYP3A7—Irinotecan—colon cancer	0.0481	0.104	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Irinotecan—colon cancer	0.0481	0.104	CbGbCtD
Fluvoxamine—CYP2B6—Irinotecan—colon cancer	0.0458	0.0986	CbGbCtD
Fluvoxamine—CYP3A7-CYP3A51P—Vincristine—colon cancer	0.0421	0.0905	CbGbCtD
Fluvoxamine—CYP3A7—Vincristine—colon cancer	0.0421	0.0905	CbGbCtD
Fluvoxamine—CYP2C9—Capecitabine—colon cancer	0.0392	0.0843	CbGbCtD
Fluvoxamine—CYP3A5—Irinotecan—colon cancer	0.0361	0.0776	CbGbCtD
Fluvoxamine—CYP3A5—Vincristine—colon cancer	0.0316	0.0679	CbGbCtD
Fluvoxamine—CYP1A2—Fluorouracil—colon cancer	0.0258	0.0555	CbGbCtD
Fluvoxamine—ABCB1—Irinotecan—colon cancer	0.0235	0.0505	CbGbCtD
Fluvoxamine—CYP2C9—Fluorouracil—colon cancer	0.0232	0.05	CbGbCtD
Fluvoxamine—ABCB1—Vincristine—colon cancer	0.0205	0.0442	CbGbCtD
Fluvoxamine—CYP3A4—Irinotecan—colon cancer	0.0141	0.0303	CbGbCtD
Fluvoxamine—ABCB1—Methotrexate—colon cancer	0.0124	0.0267	CbGbCtD
Fluvoxamine—CYP3A4—Vincristine—colon cancer	0.0123	0.0265	CbGbCtD
Fluvoxamine—CYP3A7—liver—colon cancer	0.000256	0.043	CbGeAlD
Fluvoxamine—SIGMAR1—smooth muscle tissue—colon cancer	0.000233	0.0391	CbGeAlD
Fluvoxamine—CYP3A7-CYP3A51P—liver—colon cancer	0.000218	0.0365	CbGeAlD
Fluvoxamine—Epistaxis—Capecitabine—colon cancer	0.000206	0.00106	CcSEcCtD
Fluvoxamine—Discomfort—Fluorouracil—colon cancer	0.000206	0.00106	CcSEcCtD
Fluvoxamine—Shock—Irinotecan—colon cancer	0.000205	0.00106	CcSEcCtD
Fluvoxamine—Nervous system disorder—Irinotecan—colon cancer	0.000204	0.00105	CcSEcCtD
Fluvoxamine—Agranulocytosis—Capecitabine—colon cancer	0.000204	0.00105	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Irinotecan—colon cancer	0.000204	0.00105	CcSEcCtD
Fluvoxamine—Anorexia—Vincristine—colon cancer	0.000204	0.00105	CcSEcCtD
Fluvoxamine—Irritability—Methotrexate—colon cancer	0.000202	0.00104	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Irinotecan—colon cancer	0.000201	0.00104	CcSEcCtD
Fluvoxamine—Confusional state—Fluorouracil—colon cancer	0.000201	0.00104	CcSEcCtD
Fluvoxamine—Mood swings—Methotrexate—colon cancer	0.0002	0.00103	CcSEcCtD
Fluvoxamine—Hypotension—Vincristine—colon cancer	0.0002	0.00103	CcSEcCtD
Fluvoxamine—Bradycardia—Capecitabine—colon cancer	0.0002	0.00103	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Fluorouracil—colon cancer	0.000199	0.00103	CcSEcCtD
Fluvoxamine—Oedema—Fluorouracil—colon cancer	0.000199	0.00103	CcSEcCtD
Fluvoxamine—Anorexia—Irinotecan—colon cancer	0.000199	0.00102	CcSEcCtD
Fluvoxamine—Ataxia—Methotrexate—colon cancer	0.000199	0.00102	CcSEcCtD
Fluvoxamine—Infection—Fluorouracil—colon cancer	0.000198	0.00102	CcSEcCtD
Fluvoxamine—Haemoglobin—Capecitabine—colon cancer	0.000197	0.00102	CcSEcCtD
Fluvoxamine—Rhinitis—Capecitabine—colon cancer	0.000197	0.00102	CcSEcCtD
Fluvoxamine—Hepatitis—Capecitabine—colon cancer	0.000196	0.00101	CcSEcCtD
Fluvoxamine—Haemorrhage—Capecitabine—colon cancer	0.000196	0.00101	CcSEcCtD
Fluvoxamine—Nervous system disorder—Fluorouracil—colon cancer	0.000196	0.00101	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Fluorouracil—colon cancer	0.000195	0.00101	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Capecitabine—colon cancer	0.000195	0.00101	CcSEcCtD
Fluvoxamine—Liver function test abnormal—Methotrexate—colon cancer	0.000195	0.00101	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Vincristine—colon cancer	0.000195	0.00101	CcSEcCtD
Fluvoxamine—Pharyngitis—Capecitabine—colon cancer	0.000195	0.00101	CcSEcCtD
Fluvoxamine—Tachycardia—Fluorouracil—colon cancer	0.000195	0.00101	CcSEcCtD
Fluvoxamine—Hypotension—Irinotecan—colon cancer	0.000195	0.001	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Capecitabine—colon cancer	0.000194	0.001	CcSEcCtD
Fluvoxamine—Insomnia—Vincristine—colon cancer	0.000193	0.000999	CcSEcCtD
Fluvoxamine—Oedema peripheral—Capecitabine—colon cancer	0.000193	0.000998	CcSEcCtD
Fluvoxamine—Urethral disorder—Capecitabine—colon cancer	0.000192	0.000993	CcSEcCtD
Fluvoxamine—Paraesthesia—Vincristine—colon cancer	0.000192	0.000991	CcSEcCtD
Fluvoxamine—Breast disorder—Methotrexate—colon cancer	0.000191	0.000985	CcSEcCtD
Fluvoxamine—Anorexia—Fluorouracil—colon cancer	0.00019	0.000982	CcSEcCtD
Fluvoxamine—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.00019	0.000981	CcSEcCtD
Fluvoxamine—Visual impairment—Capecitabine—colon cancer	0.000189	0.000976	CcSEcCtD
Fluvoxamine—Insomnia—Irinotecan—colon cancer	0.000188	0.000972	CcSEcCtD
Fluvoxamine—Paraesthesia—Irinotecan—colon cancer	0.000187	0.000965	CcSEcCtD
Fluvoxamine—Hypotension—Fluorouracil—colon cancer	0.000186	0.000962	CcSEcCtD
Fluvoxamine—Decreased appetite—Vincristine—colon cancer	0.000186	0.00096	CcSEcCtD
Fluvoxamine—Dyspnoea—Irinotecan—colon cancer	0.000186	0.000959	CcSEcCtD
Fluvoxamine—Erythema multiforme—Capecitabine—colon cancer	0.000186	0.000958	CcSEcCtD
Fluvoxamine—SLC6A4—digestive system—colon cancer	0.000185	0.0311	CbGeAlD
Fluvoxamine—Somnolence—Irinotecan—colon cancer	0.000185	0.000956	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Vincristine—colon cancer	0.000185	0.000953	CcSEcCtD
Fluvoxamine—Fatigue—Vincristine—colon cancer	0.000184	0.000952	CcSEcCtD
Fluvoxamine—Eye disorder—Capecitabine—colon cancer	0.000183	0.000947	CcSEcCtD
Fluvoxamine—Dyspepsia—Irinotecan—colon cancer	0.000183	0.000946	CcSEcCtD
Fluvoxamine—Tinnitus—Capecitabine—colon cancer	0.000183	0.000944	CcSEcCtD
Fluvoxamine—Constipation—Vincristine—colon cancer	0.000183	0.000944	CcSEcCtD
Fluvoxamine—Pain—Vincristine—colon cancer	0.000183	0.000944	CcSEcCtD
Fluvoxamine—Asthma—Methotrexate—colon cancer	0.000182	0.000942	CcSEcCtD
Fluvoxamine—Cardiac disorder—Capecitabine—colon cancer	0.000182	0.00094	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000182	0.000938	CcSEcCtD
Fluvoxamine—Decreased appetite—Irinotecan—colon cancer	0.000181	0.000935	CcSEcCtD
Fluvoxamine—Insomnia—Fluorouracil—colon cancer	0.00018	0.000931	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Irinotecan—colon cancer	0.00018	0.000928	CcSEcCtD
Fluvoxamine—Fatigue—Irinotecan—colon cancer	0.00018	0.000927	CcSEcCtD
Fluvoxamine—Paraesthesia—Fluorouracil—colon cancer	0.000179	0.000925	CcSEcCtD
Fluvoxamine—Pancreatitis—Methotrexate—colon cancer	0.000179	0.000924	CcSEcCtD
Fluvoxamine—Pain—Irinotecan—colon cancer	0.000178	0.000919	CcSEcCtD
Fluvoxamine—Constipation—Irinotecan—colon cancer	0.000178	0.000919	CcSEcCtD
Fluvoxamine—Angiopathy—Capecitabine—colon cancer	0.000178	0.000919	CcSEcCtD
Fluvoxamine—Dyspnoea—Fluorouracil—colon cancer	0.000178	0.000918	CcSEcCtD
Fluvoxamine—Somnolence—Fluorouracil—colon cancer	0.000177	0.000915	CcSEcCtD
Fluvoxamine—Chills—Capecitabine—colon cancer	0.000176	0.000909	CcSEcCtD
Fluvoxamine—Dyspepsia—Fluorouracil—colon cancer	0.000176	0.000906	CcSEcCtD
Fluvoxamine—Arrhythmia—Capecitabine—colon cancer	0.000175	0.000905	CcSEcCtD
Fluvoxamine—Abdominal discomfort—Methotrexate—colon cancer	0.000175	0.000903	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Vincristine—colon cancer	0.000175	0.000903	CcSEcCtD
Fluvoxamine—ABCB1—blood vessel—colon cancer	0.000173	0.0291	CbGeAlD
Fluvoxamine—Decreased appetite—Fluorouracil—colon cancer	0.000173	0.000895	CcSEcCtD
Fluvoxamine—Alopecia—Capecitabine—colon cancer	0.000173	0.000895	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000172	0.000889	CcSEcCtD
Fluvoxamine—Mental disorder—Capecitabine—colon cancer	0.000172	0.000887	CcSEcCtD
Fluvoxamine—Feeling abnormal—Irinotecan—colon cancer	0.000172	0.000886	CcSEcCtD
Fluvoxamine—Malnutrition—Capecitabine—colon cancer	0.000171	0.000882	CcSEcCtD
Fluvoxamine—Dysuria—Methotrexate—colon cancer	0.000171	0.000881	CcSEcCtD
Fluvoxamine—Pain—Fluorouracil—colon cancer	0.000171	0.000881	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Irinotecan—colon cancer	0.00017	0.000879	CcSEcCtD
Fluvoxamine—SIGMAR1—bone marrow—colon cancer	0.00017	0.0285	CbGeAlD
Fluvoxamine—Upper respiratory tract infection—Methotrexate—colon cancer	0.00017	0.000876	CcSEcCtD
Fluvoxamine—Body temperature increased—Vincristine—colon cancer	0.000169	0.000873	CcSEcCtD
Fluvoxamine—Abdominal pain—Vincristine—colon cancer	0.000169	0.000873	CcSEcCtD
Fluvoxamine—Flatulence—Capecitabine—colon cancer	0.000168	0.000869	CcSEcCtD
Fluvoxamine—Erectile dysfunction—Methotrexate—colon cancer	0.000168	0.000868	CcSEcCtD
Fluvoxamine—Dysgeusia—Capecitabine—colon cancer	0.000167	0.000863	CcSEcCtD
Fluvoxamine—Photosensitivity reaction—Methotrexate—colon cancer	0.000167	0.00086	CcSEcCtD
Fluvoxamine—Back pain—Capecitabine—colon cancer	0.000165	0.000853	CcSEcCtD
Fluvoxamine—Body temperature increased—Irinotecan—colon cancer	0.000165	0.00085	CcSEcCtD
Fluvoxamine—Abdominal pain—Irinotecan—colon cancer	0.000165	0.00085	CcSEcCtD
Fluvoxamine—Feeling abnormal—Fluorouracil—colon cancer	0.000164	0.000849	CcSEcCtD
Fluvoxamine—Muscle spasms—Capecitabine—colon cancer	0.000164	0.000848	CcSEcCtD
Fluvoxamine—Pneumonia—Methotrexate—colon cancer	0.000164	0.000845	CcSEcCtD
Fluvoxamine—Drowsiness—Methotrexate—colon cancer	0.000163	0.00084	CcSEcCtD
Fluvoxamine—CYP1A1—epithelium—colon cancer	0.000163	0.0273	CbGeAlD
Fluvoxamine—SIGMAR1—vagina—colon cancer	0.000163	0.0273	CbGeAlD
Fluvoxamine—Depression—Methotrexate—colon cancer	0.000162	0.000838	CcSEcCtD
Fluvoxamine—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000161	0.000833	CcSEcCtD
Fluvoxamine—Vision blurred—Capecitabine—colon cancer	0.000161	0.000831	CcSEcCtD
Fluvoxamine—Tremor—Capecitabine—colon cancer	0.00016	0.000826	CcSEcCtD
Fluvoxamine—Renal failure—Methotrexate—colon cancer	0.00016	0.000826	CcSEcCtD
Fluvoxamine—Stomatitis—Methotrexate—colon cancer	0.000159	0.000819	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Capecitabine—colon cancer	0.000158	0.000818	CcSEcCtD
Fluvoxamine—Urticaria—Fluorouracil—colon cancer	0.000158	0.000818	CcSEcCtD
Fluvoxamine—Conjunctivitis—Methotrexate—colon cancer	0.000158	0.000816	CcSEcCtD
Fluvoxamine—Anaemia—Capecitabine—colon cancer	0.000158	0.000815	CcSEcCtD
Fluvoxamine—Body temperature increased—Fluorouracil—colon cancer	0.000158	0.000814	CcSEcCtD
Fluvoxamine—Hypersensitivity—Vincristine—colon cancer	0.000158	0.000813	CcSEcCtD
Fluvoxamine—Sweating—Methotrexate—colon cancer	0.000156	0.000805	CcSEcCtD
Fluvoxamine—Haematuria—Methotrexate—colon cancer	0.000155	0.000801	CcSEcCtD
Fluvoxamine—Malaise—Capecitabine—colon cancer	0.000154	0.000795	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Methotrexate—colon cancer	0.000154	0.000794	CcSEcCtD
Fluvoxamine—CYP2C19—digestive system—colon cancer	0.000154	0.0258	CbGeAlD
Fluvoxamine—Epistaxis—Methotrexate—colon cancer	0.000153	0.000792	CcSEcCtD
Fluvoxamine—Vertigo—Capecitabine—colon cancer	0.000153	0.000792	CcSEcCtD
Fluvoxamine—Hypersensitivity—Irinotecan—colon cancer	0.000153	0.000792	CcSEcCtD
Fluvoxamine—Asthenia—Vincristine—colon cancer	0.000153	0.000792	CcSEcCtD
Fluvoxamine—Syncope—Capecitabine—colon cancer	0.000153	0.000791	CcSEcCtD
Fluvoxamine—CYP1A2—renal system—colon cancer	0.000153	0.0257	CbGeAlD
Fluvoxamine—Leukopenia—Capecitabine—colon cancer	0.000153	0.000789	CcSEcCtD
Fluvoxamine—Agranulocytosis—Methotrexate—colon cancer	0.000152	0.000784	CcSEcCtD
Fluvoxamine—Palpitations—Capecitabine—colon cancer	0.000151	0.000779	CcSEcCtD
Fluvoxamine—CYP1A1—renal system—colon cancer	0.000151	0.0253	CbGeAlD
Fluvoxamine—Loss of consciousness—Capecitabine—colon cancer	0.00015	0.000775	CcSEcCtD
Fluvoxamine—Asthenia—Irinotecan—colon cancer	0.000149	0.000771	CcSEcCtD
Fluvoxamine—Cough—Capecitabine—colon cancer	0.000149	0.000769	CcSEcCtD
Fluvoxamine—CYP3A5—renal system—colon cancer	0.000147	0.0247	CbGeAlD
Fluvoxamine—Hypertension—Capecitabine—colon cancer	0.000147	0.000761	CcSEcCtD
Fluvoxamine—Hypersensitivity—Fluorouracil—colon cancer	0.000147	0.000759	CcSEcCtD
Fluvoxamine—Haemoglobin—Methotrexate—colon cancer	0.000147	0.000758	CcSEcCtD
Fluvoxamine—CYP2B6—renal system—colon cancer	0.000147	0.0246	CbGeAlD
Fluvoxamine—Diarrhoea—Vincristine—colon cancer	0.000146	0.000755	CcSEcCtD
Fluvoxamine—Haemorrhage—Methotrexate—colon cancer	0.000146	0.000754	CcSEcCtD
Fluvoxamine—Hepatitis—Methotrexate—colon cancer	0.000146	0.000754	CcSEcCtD
Fluvoxamine—Chest pain—Capecitabine—colon cancer	0.000145	0.000751	CcSEcCtD
Fluvoxamine—Myalgia—Capecitabine—colon cancer	0.000145	0.000751	CcSEcCtD
Fluvoxamine—Arthralgia—Capecitabine—colon cancer	0.000145	0.000751	CcSEcCtD
Fluvoxamine—Pharyngitis—Methotrexate—colon cancer	0.000145	0.000748	CcSEcCtD
Fluvoxamine—Anxiety—Capecitabine—colon cancer	0.000145	0.000748	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Methotrexate—colon cancer	0.000144	0.000745	CcSEcCtD
Fluvoxamine—Discomfort—Capecitabine—colon cancer	0.000144	0.000742	CcSEcCtD
Fluvoxamine—Urethral disorder—Methotrexate—colon cancer	0.000143	0.000739	CcSEcCtD
Fluvoxamine—Diarrhoea—Irinotecan—colon cancer	0.000142	0.000736	CcSEcCtD
Fluvoxamine—Dry mouth—Capecitabine—colon cancer	0.000142	0.000734	CcSEcCtD
Fluvoxamine—Dizziness—Vincristine—colon cancer	0.000141	0.00073	CcSEcCtD
Fluvoxamine—Pruritus—Fluorouracil—colon cancer	0.000141	0.000729	CcSEcCtD
Fluvoxamine—Visual impairment—Methotrexate—colon cancer	0.000141	0.000727	CcSEcCtD
Fluvoxamine—Confusional state—Capecitabine—colon cancer	0.000141	0.000726	CcSEcCtD
Fluvoxamine—Oedema—Capecitabine—colon cancer	0.000139	0.00072	CcSEcCtD
Fluvoxamine—Infection—Capecitabine—colon cancer	0.000138	0.000715	CcSEcCtD
Fluvoxamine—Erythema multiforme—Methotrexate—colon cancer	0.000138	0.000713	CcSEcCtD
Fluvoxamine—Dizziness—Irinotecan—colon cancer	0.000138	0.000711	CcSEcCtD
Fluvoxamine—CYP2E1—renal system—colon cancer	0.000138	0.0231	CbGeAlD
Fluvoxamine—Shock—Capecitabine—colon cancer	0.000137	0.000708	CcSEcCtD
Fluvoxamine—SIGMAR1—liver—colon cancer	0.000137	0.023	CbGeAlD
Fluvoxamine—Nervous system disorder—Capecitabine—colon cancer	0.000137	0.000706	CcSEcCtD
Fluvoxamine—Eye disorder—Methotrexate—colon cancer	0.000136	0.000705	CcSEcCtD
Fluvoxamine—Diarrhoea—Fluorouracil—colon cancer	0.000136	0.000705	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Capecitabine—colon cancer	0.000136	0.000705	CcSEcCtD
Fluvoxamine—Tinnitus—Methotrexate—colon cancer	0.000136	0.000703	CcSEcCtD
Fluvoxamine—Tachycardia—Capecitabine—colon cancer	0.000136	0.000702	CcSEcCtD
Fluvoxamine—Vomiting—Vincristine—colon cancer	0.000136	0.000702	CcSEcCtD
Fluvoxamine—CYP2C19—vagina—colon cancer	0.000136	0.0227	CbGeAlD
Fluvoxamine—Cardiac disorder—Methotrexate—colon cancer	0.000136	0.0007	CcSEcCtD
Fluvoxamine—Rash—Vincristine—colon cancer	0.000135	0.000696	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Capecitabine—colon cancer	0.000135	0.000696	CcSEcCtD
Fluvoxamine—Dermatitis—Vincristine—colon cancer	0.000135	0.000695	CcSEcCtD
Fluvoxamine—Headache—Vincristine—colon cancer	0.000134	0.000692	CcSEcCtD
Fluvoxamine—Anorexia—Capecitabine—colon cancer	0.000133	0.000686	CcSEcCtD
Fluvoxamine—Angiopathy—Methotrexate—colon cancer	0.000133	0.000684	CcSEcCtD
Fluvoxamine—Vomiting—Irinotecan—colon cancer	0.000132	0.000684	CcSEcCtD
Fluvoxamine—Dizziness—Fluorouracil—colon cancer	0.000132	0.000681	CcSEcCtD
Fluvoxamine—Rash—Irinotecan—colon cancer	0.000131	0.000678	CcSEcCtD
Fluvoxamine—Dermatitis—Irinotecan—colon cancer	0.000131	0.000677	CcSEcCtD
Fluvoxamine—Chills—Methotrexate—colon cancer	0.000131	0.000677	CcSEcCtD
Fluvoxamine—Headache—Irinotecan—colon cancer	0.00013	0.000674	CcSEcCtD
Fluvoxamine—Hypotension—Capecitabine—colon cancer	0.00013	0.000672	CcSEcCtD
Fluvoxamine—Alopecia—Methotrexate—colon cancer	0.000129	0.000666	CcSEcCtD
Fluvoxamine—Mental disorder—Methotrexate—colon cancer	0.000128	0.000661	CcSEcCtD
Fluvoxamine—Malnutrition—Methotrexate—colon cancer	0.000127	0.000656	CcSEcCtD
Fluvoxamine—Nausea—Vincristine—colon cancer	0.000127	0.000656	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000127	0.000656	CcSEcCtD
Fluvoxamine—Vomiting—Fluorouracil—colon cancer	0.000127	0.000655	CcSEcCtD
Fluvoxamine—Insomnia—Capecitabine—colon cancer	0.000126	0.000651	CcSEcCtD
Fluvoxamine—Rash—Fluorouracil—colon cancer	0.000126	0.000649	CcSEcCtD
Fluvoxamine—Dermatitis—Fluorouracil—colon cancer	0.000126	0.000649	CcSEcCtD
Fluvoxamine—CYP1A2—digestive system—colon cancer	0.000125	0.021	CbGeAlD
Fluvoxamine—Paraesthesia—Capecitabine—colon cancer	0.000125	0.000646	CcSEcCtD
Fluvoxamine—Headache—Fluorouracil—colon cancer	0.000125	0.000645	CcSEcCtD
Fluvoxamine—Dysgeusia—Methotrexate—colon cancer	0.000125	0.000643	CcSEcCtD
Fluvoxamine—Dyspnoea—Capecitabine—colon cancer	0.000124	0.000642	CcSEcCtD
Fluvoxamine—Nausea—Irinotecan—colon cancer	0.000124	0.000639	CcSEcCtD
Fluvoxamine—CYP1A1—digestive system—colon cancer	0.000124	0.0208	CbGeAlD
Fluvoxamine—Back pain—Methotrexate—colon cancer	0.000123	0.000635	CcSEcCtD
Fluvoxamine—Dyspepsia—Capecitabine—colon cancer	0.000123	0.000633	CcSEcCtD
Fluvoxamine—CYP2B6—lymphoid tissue—colon cancer	0.000122	0.0204	CbGeAlD
Fluvoxamine—Decreased appetite—Capecitabine—colon cancer	0.000121	0.000626	CcSEcCtD
Fluvoxamine—CYP3A5—digestive system—colon cancer	0.000121	0.0203	CbGeAlD
Fluvoxamine—Gastrointestinal disorder—Capecitabine—colon cancer	0.00012	0.000621	CcSEcCtD
Fluvoxamine—CYP2B6—digestive system—colon cancer	0.00012	0.0202	CbGeAlD
Fluvoxamine—Fatigue—Capecitabine—colon cancer	0.00012	0.00062	CcSEcCtD
Fluvoxamine—Vision blurred—Methotrexate—colon cancer	0.00012	0.000619	CcSEcCtD
Fluvoxamine—Pain—Capecitabine—colon cancer	0.000119	0.000615	CcSEcCtD
Fluvoxamine—Constipation—Capecitabine—colon cancer	0.000119	0.000615	CcSEcCtD
Fluvoxamine—CYP2C9—digestive system—colon cancer	0.000119	0.02	CbGeAlD
Fluvoxamine—Nausea—Fluorouracil—colon cancer	0.000118	0.000612	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Methotrexate—colon cancer	0.000118	0.000609	CcSEcCtD
Fluvoxamine—Anaemia—Methotrexate—colon cancer	0.000118	0.000607	CcSEcCtD
Fluvoxamine—Feeling abnormal—Capecitabine—colon cancer	0.000115	0.000593	CcSEcCtD
Fluvoxamine—Malaise—Methotrexate—colon cancer	0.000115	0.000592	CcSEcCtD
Fluvoxamine—CYP2C19—liver—colon cancer	0.000114	0.0192	CbGeAlD
Fluvoxamine—Vertigo—Methotrexate—colon cancer	0.000114	0.00059	CcSEcCtD
Fluvoxamine—CYP2E1—lymphoid tissue—colon cancer	0.000114	0.0192	CbGeAlD
Fluvoxamine—Gastrointestinal pain—Capecitabine—colon cancer	0.000114	0.000588	CcSEcCtD
Fluvoxamine—Leukopenia—Methotrexate—colon cancer	0.000114	0.000588	CcSEcCtD
Fluvoxamine—CYP2E1—digestive system—colon cancer	0.000113	0.0189	CbGeAlD
Fluvoxamine—Cough—Methotrexate—colon cancer	0.000111	0.000573	CcSEcCtD
Fluvoxamine—Urticaria—Capecitabine—colon cancer	0.000111	0.000572	CcSEcCtD
Fluvoxamine—CYP3A4—renal system—colon cancer	0.000111	0.0186	CbGeAlD
Fluvoxamine—Body temperature increased—Capecitabine—colon cancer	0.00011	0.000569	CcSEcCtD
Fluvoxamine—Abdominal pain—Capecitabine—colon cancer	0.00011	0.000569	CcSEcCtD
Fluvoxamine—Convulsion—Methotrexate—colon cancer	0.00011	0.000569	CcSEcCtD
Fluvoxamine—CYP1A1—vagina—colon cancer	0.000109	0.0183	CbGeAlD
Fluvoxamine—CYP2D6—renal system—colon cancer	0.000109	0.0183	CbGeAlD
Fluvoxamine—Arthralgia—Methotrexate—colon cancer	0.000108	0.000559	CcSEcCtD
Fluvoxamine—Myalgia—Methotrexate—colon cancer	0.000108	0.000559	CcSEcCtD
Fluvoxamine—Chest pain—Methotrexate—colon cancer	0.000108	0.000559	CcSEcCtD
Fluvoxamine—Discomfort—Methotrexate—colon cancer	0.000107	0.000552	CcSEcCtD
Fluvoxamine—CYP3A5—vagina—colon cancer	0.000107	0.0179	CbGeAlD
Fluvoxamine—CYP2B6—vagina—colon cancer	0.000106	0.0178	CbGeAlD
Fluvoxamine—SIGMAR1—lymph node—colon cancer	0.000105	0.0176	CbGeAlD
Fluvoxamine—Confusional state—Methotrexate—colon cancer	0.000105	0.00054	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Methotrexate—colon cancer	0.000104	0.000536	CcSEcCtD
Fluvoxamine—ABCB1—embryo—colon cancer	0.000103	0.0174	CbGeAlD
Fluvoxamine—Infection—Methotrexate—colon cancer	0.000103	0.000532	CcSEcCtD
Fluvoxamine—Hypersensitivity—Capecitabine—colon cancer	0.000103	0.00053	CcSEcCtD
Fluvoxamine—Nervous system disorder—Methotrexate—colon cancer	0.000102	0.000525	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Methotrexate—colon cancer	0.000102	0.000525	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Methotrexate—colon cancer	0.0001	0.000518	CcSEcCtD
Fluvoxamine—Asthenia—Capecitabine—colon cancer	0.0001	0.000516	CcSEcCtD
Fluvoxamine—Anorexia—Methotrexate—colon cancer	9.89e-05	0.000511	CcSEcCtD
Fluvoxamine—Pruritus—Capecitabine—colon cancer	9.86e-05	0.000509	CcSEcCtD
Fluvoxamine—Hypotension—Methotrexate—colon cancer	9.7e-05	0.000501	CcSEcCtD
Fluvoxamine—Diarrhoea—Capecitabine—colon cancer	9.54e-05	0.000492	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Methotrexate—colon cancer	9.45e-05	0.000488	CcSEcCtD
Fluvoxamine—Insomnia—Methotrexate—colon cancer	9.39e-05	0.000485	CcSEcCtD
Fluvoxamine—CYP1A2—liver—colon cancer	9.34e-05	0.0157	CbGeAlD
Fluvoxamine—Paraesthesia—Methotrexate—colon cancer	9.32e-05	0.000481	CcSEcCtD
Fluvoxamine—Dyspnoea—Methotrexate—colon cancer	9.25e-05	0.000478	CcSEcCtD
Fluvoxamine—Somnolence—Methotrexate—colon cancer	9.22e-05	0.000476	CcSEcCtD
Fluvoxamine—Dizziness—Capecitabine—colon cancer	9.22e-05	0.000476	CcSEcCtD
Fluvoxamine—CYP1A1—liver—colon cancer	9.22e-05	0.0155	CbGeAlD
Fluvoxamine—Dyspepsia—Methotrexate—colon cancer	9.13e-05	0.000472	CcSEcCtD
Fluvoxamine—CYP3A4—digestive system—colon cancer	9.08e-05	0.0152	CbGeAlD
Fluvoxamine—Decreased appetite—Methotrexate—colon cancer	9.02e-05	0.000466	CcSEcCtD
Fluvoxamine—CYP3A5—liver—colon cancer	9.01e-05	0.0151	CbGeAlD
Fluvoxamine—Gastrointestinal disorder—Methotrexate—colon cancer	8.96e-05	0.000462	CcSEcCtD
Fluvoxamine—CYP2B6—liver—colon cancer	8.96e-05	0.015	CbGeAlD
Fluvoxamine—Fatigue—Methotrexate—colon cancer	8.95e-05	0.000462	CcSEcCtD
Fluvoxamine—CYP2D6—digestive system—colon cancer	8.93e-05	0.015	CbGeAlD
Fluvoxamine—Pain—Methotrexate—colon cancer	8.87e-05	0.000458	CcSEcCtD
Fluvoxamine—CYP2C9—liver—colon cancer	8.87e-05	0.0149	CbGeAlD
Fluvoxamine—Vomiting—Capecitabine—colon cancer	8.86e-05	0.000458	CcSEcCtD
Fluvoxamine—Rash—Capecitabine—colon cancer	8.79e-05	0.000454	CcSEcCtD
Fluvoxamine—Dermatitis—Capecitabine—colon cancer	8.78e-05	0.000453	CcSEcCtD
Fluvoxamine—Headache—Capecitabine—colon cancer	8.73e-05	0.000451	CcSEcCtD
Fluvoxamine—Feeling abnormal—Methotrexate—colon cancer	8.55e-05	0.000441	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Methotrexate—colon cancer	8.49e-05	0.000438	CcSEcCtD
Fluvoxamine—ABCB1—epithelium—colon cancer	8.45e-05	0.0142	CbGeAlD
Fluvoxamine—CYP2E1—liver—colon cancer	8.4e-05	0.0141	CbGeAlD
Fluvoxamine—Nausea—Capecitabine—colon cancer	8.28e-05	0.000427	CcSEcCtD
Fluvoxamine—Urticaria—Methotrexate—colon cancer	8.24e-05	0.000426	CcSEcCtD
Fluvoxamine—Body temperature increased—Methotrexate—colon cancer	8.2e-05	0.000423	CcSEcCtD
Fluvoxamine—Abdominal pain—Methotrexate—colon cancer	8.2e-05	0.000423	CcSEcCtD
Fluvoxamine—ABCB1—renal system—colon cancer	7.83e-05	0.0131	CbGeAlD
Fluvoxamine—Hypersensitivity—Methotrexate—colon cancer	7.64e-05	0.000395	CcSEcCtD
Fluvoxamine—Asthenia—Methotrexate—colon cancer	7.44e-05	0.000384	CcSEcCtD
Fluvoxamine—Pruritus—Methotrexate—colon cancer	7.34e-05	0.000379	CcSEcCtD
Fluvoxamine—Diarrhoea—Methotrexate—colon cancer	7.1e-05	0.000367	CcSEcCtD
Fluvoxamine—CYP1A1—lymph node—colon cancer	7.07e-05	0.0119	CbGeAlD
Fluvoxamine—Dizziness—Methotrexate—colon cancer	6.86e-05	0.000354	CcSEcCtD
Fluvoxamine—CYP3A4—liver—colon cancer	6.76e-05	0.0113	CbGeAlD
Fluvoxamine—CYP2D6—liver—colon cancer	6.65e-05	0.0112	CbGeAlD
Fluvoxamine—Vomiting—Methotrexate—colon cancer	6.6e-05	0.000341	CcSEcCtD
Fluvoxamine—Rash—Methotrexate—colon cancer	6.54e-05	0.000338	CcSEcCtD
Fluvoxamine—Dermatitis—Methotrexate—colon cancer	6.54e-05	0.000337	CcSEcCtD
Fluvoxamine—ABCB1—lymphoid tissue—colon cancer	6.5e-05	0.0109	CbGeAlD
Fluvoxamine—Headache—Methotrexate—colon cancer	6.5e-05	0.000336	CcSEcCtD
Fluvoxamine—ABCB1—digestive system—colon cancer	6.43e-05	0.0108	CbGeAlD
Fluvoxamine—Nausea—Methotrexate—colon cancer	6.16e-05	0.000318	CcSEcCtD
Fluvoxamine—ABCB1—bone marrow—colon cancer	5.92e-05	0.00994	CbGeAlD
Fluvoxamine—ABCB1—vagina—colon cancer	5.67e-05	0.00952	CbGeAlD
Fluvoxamine—ABCB1—liver—colon cancer	4.79e-05	0.00803	CbGeAlD
Fluvoxamine—ABCB1—lymph node—colon cancer	3.67e-05	0.00616	CbGeAlD
